Abstract: A carrier for a spare tire of a vehicle includes a base, a mount, and a locking member. The base is configured to be coupled to the vehicle. The mount is coupled to the base and pivotable relative to the base about a pivot axis. The mount is configured to support the spare tire for common rotation with the mount about the pivot axis. The pivot axis is offset from a central axis of the spare tire when the spare tire is supported by the mount. The locking member is movable between a locked position wherein the locking member engages the mount and the base to prevent relative movement therebetween, and an unlocked position wherein the mount is pivotable relative to the base.

Abstract: A carrier for a spare tire of a vehicle includes a base, a mount, and a locking member. The base is configured to be coupled to the vehicle. The mount is coupled to the base and pivotable relative to the base about a pivot axis. The mount is configured to support the spare tire for common rotation with the mount about the pivot axis. The pivot axis is offset from a central axis of the spare tire when the spare tire is supported by the mount. The locking member is movable between a locked position wherein the locking member engages the mount and the base to prevent relative movement therebetween, and an unlocked position wherein the mount is pivotable relative to the base.

Abstract: The present invention provides an immunogenic composition capable of eliciting an immune response when administered to a human or non-human animal, wherein the composition comprises an isolated protein with one or more of the following properties: i) about 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or more percent sequence identity to the protein of SEQ ID No: 1 or a fragment, derivative or analog thereof; ii) is a modified factor H binding protein, wherein the factor H binding protein has been modified at least at the position equivalent to position 318 as defined in FIG. 6 (SEQ ID No: 2); iii) does not bind to factor H; and iv) the immune response elicited is cross reactive with two or more of variant 1 factor H binding protein, variant 2 factor H binding protein and variant 3 factor H binding protein from N. meningitidis; and uses thereof.

Abstract: Various polypeptides, or a variant or fragment thereof or a fusion of these are described which are useful in a vaccine. The polypeptide may be a polypeptide comprising the amino acid sequence selected from any one of SEQ ID Nos 2, 4, 6, 8, 10, 12, 14; or a fragment or variant thereof or a fusion of such a fragment or variant, and is useful in a vaccine against Neisseria meningitidis.

Abstract: Various polypeptides, or a variant or fragment thereof or a fusion of these are described which are useful in a vaccine. The polypeptide may be a polypeptide comprising the amino acid sequence selected from any one of SEQ ID Nos (2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68); or a fragment or variant thereof or a fusion of such fragment or variant, and is useful in a vaccine against Neisseira meningitidis.